

## Product datasheet for TL301364

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ST6GALNAC1 Human shRNA Plasmid Kit (Locus ID 55808)**

### **Product data:**

**Product Type:** shRNA Plasmids

**Product Name:** ST6GALNAC1 Human shRNA Plasmid Kit (Locus ID 55808)

**Locus ID:** 55808

Synonyms: HSY11339; SIAT7A; ST6GalNAcl; STYI

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

Components: ST6GALNAC1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID =

55808). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001289107, NM 018414, NR 110309, NM 018414.1, NM 018414.2, NM 018414.3,

NM 018414.4, NM 001289107.1, BC022462, BC063830, NM 001289107.2, NM 018414.5

UniProt ID: Q9NSC7

**Summary:** Glycosylation of proteins affects cell-cell interaction, interactions with the matrix, and the

functions of intracellular molecules. ST6GALNAC1 transfers a sialic acid, N-acetylneuraminic acid (NeuAc), in an alpha-2,6 linkage to O-linked GalNAc residues. The cancer-associated sialyl-Tn (sTn) antigen is formed by ST6GALNAC1-catalyzed sialylation of GalNAc residues on mucins (Ikehara et al., 1999 [PubMed 10536037]; Sewell et al., 2006 [PubMed 16319059]).

[supplied by OMIM, Mar 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).